Chimerix’s (CMRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a report published on Monday morning,Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock.

Several other equities analysts have also recently weighed in on CMRX. StockNews.com raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st. Wedbush restated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research note on Thursday, November 7th.

Chimerix Price Performance

Chimerix stock opened at $0.95 on Monday. The company has a market cap of $85.44 million, a price-to-earnings ratio of -1.01 and a beta of 1.13. The firm has a 50-day moving average of $0.90 and a 200-day moving average of $0.91. Chimerix has a one year low of $0.75 and a one year high of $1.30.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the company posted ($0.21) earnings per share. As a group, sell-side analysts expect that Chimerix will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Chimerix

Several institutional investors and hedge funds have recently modified their holdings of CMRX. Koshinski Asset Management Inc. bought a new stake in shares of Chimerix during the 1st quarter worth about $42,000. Acadian Asset Management LLC boosted its holdings in shares of Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock worth $2,304,000 after acquiring an additional 291,981 shares during the period. Marshall Wace LLP acquired a new position in shares of Chimerix in the second quarter valued at approximately $137,000. Valeo Financial Advisors LLC increased its stake in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.